provide effective analgesia after orthopaedic surgery and reduce opioid requirements. The need for parenteral NSAIDs with peripheral surgery is controversial. In this study 10 patients were treated with oral tenoxicam 20 mg preoperatively, and at 4 hours and 28 hours after knee ligament reconstruction surgery. Plasma concentrations of tenoxicam, an NSAID with a long elimination half-life, were measured for 10 days. All patients received patient-controlled intravenous morphine postoperatively, which delayed absorption of the second and third tenoxicam doses. However, plasma concentrations of tenoxicam were achieved and maintained for the five-day surgical admission above the level considered to produce effective analgesia. Oral analgesic administration is a simple and feasible option in the perioperative period.
Although parenteral opioid analgesia is generally required after major surgery, opioid dosage and sideeffects can be reduced by the use of non-steroidal anti-inflammatory drugs (NSAIDs) [1] [2] [3] . The combined use of opioids and NSAIDs may also improve analgesia associated with their different mechanisms of action 4 . NSAIDs provide effective analgesia for peripheral orthopaedic surgery [5] [6] [7] , which is often performed in younger patients, less likely to have contraindications to the use of NSAIDs. Good analgesia facilitates early mobilization and discharge. In selecting an NSAID for perioperative use, pharmacokinetic properties may be more significant than minor differences in pharmacodynamics between drugs. As ketorolac is the only NSAID available for parenteral use in Australia, we have explored the perioperative oral use of a long-acting NSAID, tenoxicam. Our aim was to provide reliable and effective plasma concentrations for a five-day surgical admission with a simple oral dose schedule and concomitant opioid use. Parenteral tenoxicam is effective after major surgery with a duration of action about twelve hours after a single dose 8 . Tenoxicam kinetics with oral administration in the perioperative period had not previously been investigated.
METHODS
The study was approved by the Scientific and Ethics Committee of the Royal Melbourne Hospital Research Foundation. Informed consent was obtained from 10 patients scheduled for knee reconstruction surgery (cruciate ligament repair as a combined open and arthroscopic procedure). Patients with renal or hepatic impairment, chronic pain with opioid use, hypersensitivity to aspirin, pregnancy or requiring medication known to interfere with drug disposition, were excluded. Haematology and clinical chemistry testing were performed up to 48 hours prior to surgery and on the day following completion of tenoxicam therapy.
After premedication with oral temazepam 10 mg one hour prior to surgery, anaesthesia was induced with propofol 2-3 mg/kg and maintained with nitrous oxide and isoflurane. A central venous catheter was inserted via the cubital fossa prior to induction to facilitate blood sampling. An initial dose of morphine (0.1 mg/kg IV) was administered on induction and crystalloid, 10 ml/kg given over 30 minutes. Postoperative analgesia was continued for at least 24 hours with patient-controlled intravenous morphine using an Abbott infusion pump. The bolus morphine dose was 1 mg and the lockout interval five minutes.
Tenoxicam, 20 mg orally, was administered two hours prior to the scheduled start of surgery, and as near as possible to four hours and 24 hours after the completion of surgery. Venous blood samples (3 ml) for tenoxicam assay were collected just prior to the first dose, and at approximately 0.5, 1, 1.5, 2, 2.5, 4, 5 and 6 hours (prior to the second dose). Further samples were taken at approximately 0.5, 1, 1.5, 2, 2.5, 4, 8, 12 and 24 hours after the second and third doses as well as 48, 144 and 192 hours after the third (final) dose.
Tenoxicam concentrations were measured using a modified HPLC method 9 . Plasma (1 ml) containing tenoxicam, along with 25 µl piroxicam 100 mg/l as the internal standard, was acidified with 2 ml potassium dihydrogen phosphate buffer 100 mM and extracted into 3 ml dichloromethane in a polypropylene tube. The dichloromethane phase was transferred to a second polypropylene tube and evaporated to dryness under nitrogen at 40°C. The residue was reconstituted in mobile phase (200 µl). The mobile phase was 32:68 methanol: 100mM potassium dihydrogen phosphate at pH 5.6, running through a 150 x 3.9 mm Novapak C 18 column at 0.8 ml/min with detection by UV absorbance at 371 nm. Exposure of solutions containing tenoxicam to light was kept to a minimum. The assay was linear to at least 20 mg/l with a detection limit of 0.01 mg/l and a within-day co-efficient of variation of 4.6% (n=8) at 1 mg/l.
One-and two-compartment mamillary models with first-order absorption of tenoxicam following oral dosing were fitted to the plasma concentration versus time data for each patient individually using extended least-squares nonlinear regression 10 . Extended leastsquares nonlinear regression employs a likelihoodbased objective function related to ordinary leastsquares, but with a model for the variance of the data such that the objective function weights each squared deviation by the expected variance (constant coefficient of variance error model) 11 . Models were expressed in terms of central compartment volume (V 2 ), clearance (Cl), rate constant for oral absorption (ka) and, for two compartment models, intercompartment clearance (Cldist, describing the movement of drug from central to peripheral compartment, equal to V 1 . k 12 ) and peripheral volume (V 2 ). As all tenoxicam doses were administered orally, the apparent pharmacokinetic parameters represent the ratio of true volume or clearance to oral bioavailability (i.e. apparent Cl is really Cl/F, apparent V is really V/F, where F is the bioavailability fraction).
A stepwise approach similar to multiple stepwise linear regression was used to optimize the pharmacokinetic model for each patient. The inclusion of additional pharmacokinetic parameters in the model building process was considered according to the following criteria: the difference in -2 log likelihood (the objective function which is approximately Chisquare distributed), plots of the unweighted and weighted residuals, along with the traditional F-ratio test [10] [11] . In particular the use of different rates of firstorder absorption for each dose and a lag-time before absorption were assessed for their ability to improve both one and two compartment models.
Change in absorption half-life was assessed using Student's t-test with the Bonferroni correction for multiple comparisons. The relationship between pharmacokinetic parameters and weight and age were assessed with simple linear regression.
RESULTS
Blood sampling over 10 days to determine the pharmacokinetics of tenoxicam was completed in 10 patients (7 males, 3 females) of mean age 25 years (range 20-39 years) and mean weight 80 kg (range 67-104 kg). The mean morphine requirement for the first 24 hours after surgery was 44 mg (SEM 8.5, range 7-96 mg) and the mean analog pain score for this period (scale 0-10) was 2.8 (SEM 0.4, range 1.4-4.1). No clinically significant changes were noted with haematology and biochemistry testing.
It was not possible to differentiate between oneand two-compartment models when a single absorption rate constant was used for the three tenoxicam doses. Allowing individual estimates of the rate of absorption of tenoxicam for each dose improved the fit of the data for all patients with both one-and twocompartment models (P<0.05 for both the objective function and F-ratio tests for all patients with both one-and two-compartment models). Using separate absorption rate constants enabled comparison of oneand two-compartment models, with the two-compartment model providing a significantly better fit to the data for all patients (P<0.05 for both objective function and F-ratio in each case). The inclusion of a lagtime for absorption after oral dosing further improved the fit of the two-compartment model (P<0.05 in each case). However, it was not possible to assign individual lag-times for each dose. The pharmacokinetic parameters are presented in Table 1 .
Mean fitted plasma tenoxicam concentration in the ten patients are shown in Figure 1 . For clarity, the timing of the tenoxicam doses has been adjusted so as to coincide in all patients, and the plasma tenoxicam concentrations simulated for those times according to the pharmacokinetic parameters for each patient.
The rate constant for absorption of tenoxicam was reduced for the second dose (P<0.01) and did not recover significantly. No significant relationship was Anaesthesia and Intensive Care, Vol. 25, No. 2, April 1997 detected between any of the other pharmacokinetic parameters (Cl/F, Cl dist /F, V 1 /F, or V ss /F) and weight or age.
DISCUSSION
Our results indicate that the clearance and distribution volumes of tenoxicam in young surgical patients are similar to those previously observed for healthy volunteers following a single oral dose. Previous reports for healthy volunteers have demonstrated mean apparent clearances (Cl/F) of 0.079 to 0.133 l/h, mean apparent distribution volumes (V ss /F) of 7.8 to 11.5 l and mean elimination half-lives of 60 to 81h 12 , all of which compare favourably with our results (Table 1) . While the absorption of the first oral dose in our patients was similar to that in other reports, the absorption of the second and third doses was markedly delayed; approximately tenfold compared to the first dose. This is presumably secondary to the reduction in gastrointestinal motility from the concomitant administration of opioid analgesics, although postoperative ileus and cholestasis may also affect drug absorption. Furthermore, the similarity of the estimates of Cl/F and V ss /F in our patients to previous reports provides indirect evidence that the bioavailability fraction (F) did not change appreciably from the reported value of 1 15 , even though the rate of tenoxicam absorption was markedly reduced for the second and third doses. The lack of clear relationship between the pharmacokinetic parameters and weight or age is probably an artefact of the homogeneous nature of the patients as such relationships have been observed previously 15 .
Less consideration has been given to the delivery of NSAIDs than for opioids in the perioperative period. It is often assumed that the parenteral route for analgesia must be chosen during and after surgery because of the delay in gastric emptying and incidence of nausea and vomiting associated with the use of opioids. Ketorolac is the only NSAID available for parenteral use in Australia. Although the possibility of intraoperative delivery provides some advantage, even when given intravenously the time to peak effect for ketorolac 4 is delayed compared with an opioid such as fentanyl 3 . Combining the use of an opioid and NSAID in the perioperative period can improve the quality of analgesia, although the opioid dose may not be reduced when this is patientcontrolled 14 .
A more appropriate role for the NSAID may be to provide an effective background analgesia (with a plasma concentration continuously in the therapeutic range), which is supplemented by opioids during surgical stimulation or postoperative movement. Maximum benefit from the NSAID would be expected if a therapeutic concentration was achieved preoperatively for a preemptive analgesic effect, then maintained during postoperative recovery. Fletcher et al 7 found that ketorolac 60 mg IV was effective in reducing the pain scores of orthopaedic patients in the recovery ward if given prior to induction rather than at the conclusion of the anaesthetic. Effective analgesia with continuous intramuscular infusion of ketorolac has been reported 5 , but intramuscular infusion is not a widely practised technique. A preemptive analgesic effect has also been demonstrated when a long-acting NSAID such as piroxicam is given as an oral premedication 15 . Failure to demonstrate this in studies with other NSAIDs may be due to failure to ensure that an adequate plasma concentration profile is achieved perioperatively 16 . The plasma concentration of tenoxicam for maximum efficacy in the relief of acute postoperative pain has not been directly determined, however a single 20 mg tenoxicam dose IV was reported to significantly decrease morphine consumption in the 12 hours after thoracotomy with a greater effect in the initial four hours 8 . No analgesic effect was demonstrated in that study between 12 and 24 hours, indicating that further doses are needed to maintain a therapeutic plasma concentration. In addition, Balzarena 17 reported analgesia prolonged to six hours after spinal anaesthesia for caesarean section, while Elhakim and Naffie 18 found that opioid consumption was reduced to 50% of control on the first day after caesarean section and time to first request for analgesia prolonged to almost two hours with a tenoxicam dose prior to induction of anaesthesia. Although plasma concentrations were not measured in any of these studies, the pharmacokinetics of a single IV dose of 20 mg tenoxicam has been well established in volunteers 19 . Plasma concentrations decline to approximately 2 µg/ml at about two hours, remaining above 1.5 µg/ml to six to eight hours, indicating that effective therapeutic effects are achieved at approximately 2 µg/ml and above.
Our study demonstrates that a target plasma concentration of tenoxicam can be reliably maintained with oral administration perioperatively, even though the postoperative absorption is slowed by concomitant opioid use. Absorption of the drug resulted in increased peak plasma concentration with each dose, and maintenance of plasma concentrations above 2 µg/ml for the five-day duration of hospital stay after knee ligament reconstruction surgery. The mean pain scores achieved in patients having cruciate ligament reconstruction in our study were relatively low and judged to be acceptable by both patients and staff. Morphine requirement, set by patient control, was highly variable and was not compared with any other group as this was not an aim of the study. Use of the oral route for the NSAID avoids any confusion with opioid administration and the dose schedule is likely to achieve a high level of compliance from both patients and ward staff. An alternative to the use of an oral NSAID such as tenoxicam with a long elimination half-life would be a sustained-release preparation. Plummer et al 14 administered sustainedrelease ibuprofen tablets preoperatively and at 24 hours after lower abdominal gynaecological surgery. Their aim was to avoid the need to give a second oral dose soon after surgery (not feasible in their patient group), and to reduce opioid-related complications. There was no reduction in morphine consumption or in the incidence of side-effects, but the plasma concentration of ibuprofen was not measured, so a therapeutic concentration may not have been maintained for the full 24 hours.
In conclusion, this pharmacokinetic study indicates that a simple oral dosing schedule with tenoxicam, started preoperatively, can provide plasma concentrations suitable for background analgesia in orthopaedic patients, despite the delays in absorption caused by opioids. This can be exploited in younger patients with a low incidence of contraindications to NSAID treatment, that require early mobilization and discharge after peripheral surgery.
